FDA
-
-
-
-
-
-
-
NeuroSense receives South Korean patent for ALS drug PrimeC
-
-
-
-
-
-
-
NeuroSense reschedules Health Canada meeting to include additional data
-
-
-
-
-
-
-
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
-
-
-
-
-
-
-
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study
-
-
-
-
-
-
-
NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price
-
-
-
-
-
-
-
NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
NeuroSense Provides Business Update and Third Quarter 2024 Financial Results
-
325,893 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

